ASPIRIN CURES ERYTHROMELALGIA AND CEREBROVASCULAR DISTURBANCES IN JAK2-THROMBOCYTHEMIA THROUGH PLATELET-CYCLOXYGENASE INHIBITION – MPN Research Foundation
Skip to content
MPN Research Foundation
Facebook-f
Twitter
Instagram
Search for...
Menu
UNDERSTANDING MPNS
Primary Myelofibrosis (MF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
Glossary
ABOUT MPNRF
Our Mission and History
Board of Directors
MPNRF Team
Scientific Advisory Board
Our Research Impact
News & Articles
Newsletters
Our Partners
LIVING WITH…
MPN Clinical Trials
Find Support
Just Diagnosed
30 Facts about MPNs
Patient Bill of Rights
Patient Stories
Treatments
MAKE AN IMPACT
Make a Donation
Past Present Progress Campaign
Other Ways to Give
Create Your Own Fundraiser
MPN Clinical Trials
RESEARCH
Our Research Impact
2022 Thrive Initiative
MPN Interferon Initiative
The MPN Challenge
MPN Science Reports
Annual MPN Roundtable
Patient-Focused Drug Development
For Researchers
Apply For Funding
DONATE
SIGN UP
ASPIRIN CURES ERYTHROMELALGIA AND CEREBROVASCULAR DISTURBANCES IN JAK2-THROMBOCYTHEMIA THROUGH PLATELET-CYCLOXYGENASE INHIBITION
To view the Abstract pg this article please click
here.
Receive updates on the latest MPN news & events.
SIGN UP TODAY
Find out ways you can help support MPN patients and researchers.
MAKE AN IMPACT
MPNRF Team
Board of Directors
About MPNRF
Our Mission and History
